Compositions and methods for neuroprotection in neonatal hypoxic-ischemic encephalopathy

JP2023552450A5Inactive Publication Date: 2024-12-06THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023534312
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-12-07
Filing Date
2021-12-07
Publication Date
2024-12-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for hypoxic-ischemic encephalopathy (HIE) in newborns, such as therapeutic hypothermia, are limited in efficacy and require immediate administration within a narrow time window, often necessitating transportation to specialized facilities, which can delay treatment and are not universally effective.

Method used

Administration of omega-3 fatty acid diglycerides and triglycerides, formulated into emulsions, either intravenously to the mother during pregnancy or to the newborn, to provide neuroprotection against brain damage caused by oxygen deprivation or blood flow restriction, potentially expanding the treatment window and enhancing neuroprotection when combined with therapeutic hypothermia.

Benefits of technology

The omega-3 fatty acid emulsions demonstrate significant neuroprotective effects, reducing brain damage and extending the therapeutic window for HIE treatment, offering a viable alternative or complement to hypothermia, even when administered outside the typical time constraints.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

In various aspects and embodiments of the present disclosure, the present invention provides pharmaceutical compositions and methods for protecting against brain damage associated with hypoxic-ischemic encephalopathy (HIE) using omega-3 fatty acid (n-3 FA) diglyceride (DG) and / or triglyceride (TG) emulsions, which may be used alone or in combination with therapeutic hypothermia (HT).
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] Hypoxic-ischemic encephalopathy (HIE) is a serious disease that occurs in newborns and often causes long-term severe developmental disorders and neurological disorders such as death or cerebral palsy. HIE is caused by various conditions that result in oxygen deficiency in the brain of newborns, such as before birth, during birth, and after birth. Currently, the only established treatment for HIE is therapeutic hypothermia (HT). HT involves cooling the whole body or the brain of the newborn to about 33 - 34°C for 72 hours. Preclinical studies and small-scale clinical trials have shown that HT can reduce the degree of nerve damage, lower the mortality rate, and improve the recovery of nerve function.

[0002] However, HT has only been successful in reducing long-term neurological disorders in a small number of HIE patients (about 1 in 8), and its use is generally limited to tertiary medical facilities. Therefore, HT requires the transfer of newborns, and treatment may be delayed at an important time. HT usually needs to be started within 6 hours of the ischemic event.

Background Art

[0003] Therefore, there is an urgent need for compositions and methods that provide neuroprotection to newborns experiencing HIE or at risk of HIE.

Summary of the Invention

[0004] In various aspects and embodiments, the present invention provides pharmaceutical compositions and methods for protecting against brain damage associated with hypoxic-ischemic encephalopathy (HIE). The compositions and methods use omega-3 fatty acid (n-3 FA) diglycerides (DG) and / or triglycerides (TG) that can be incorporated into an emulsion. In accordance with various aspects and embodiments, the present disclosure provides compositions and methods for preventing or reducing brain damage in infants caused by oxygen deficiency and / or blood flow restriction during the prenatal, intrapartum, or postpartum periods.

[0005] In various embodiments, the infant is prenatal or in labor and at risk of HIE, and n-3FA DG or TG emulsion is administered intravenously to the pregnant mother. For example, in some embodiments, n-3FA DG or TG emulsion is administered intravenously to the mother when an ischemic event that may induce HIE is predicted or detected, for example, when pre-eclampsia or other pregnancy conditions associated with HIE risk are detected. In some embodiments, the emulsion is administered during labor, including prolonged labor, or when the newborn is judged to be at risk of HIE due to umbilical cord compression, or when placental blood flow is impaired, such as in placental abruption.

[0006] In other embodiments, the recipient is a neonatal (i.e., a newborn) suspected of having HIE. The n-3FA DG or TG emulsion is administered to the neonatal within approximately 12 hours of delivery, or within approximately 10 hours of delivery, or within approximately 8 hours of delivery, or within approximately 6 hours of delivery, or within approximately 4 hours of delivery, or within approximately 2 hours of delivery. For delivery to neonates, the emulsion may be administered via a nasogastric (NG) tube or intravenously.

[0007] In various embodiments, neonates are further treated with HT either before, during, or after treatment with n-3FA TG or DG emulsion. HT should typically be initiated as early as possible, such as within approximately 6 hours of delivery. However, in some embodiments, HT is initiated within approximately 12 hours, or within approximately 10 hours, or within approximately 8 hours of delivery. In some embodiments, administration of TG or DG emulsion immediately after birth may extend the extent to which HT provides benefit in avoiding brain injury and long-term and / or lifelong HIE complications.

[0008] According to the present invention, the fatty acids of DG or TG are mainly n-3 FAs. In some embodiments, the n-3 FA is a long-chain n-3 FA comprising one or more of docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), and docosapentaenoic acid (DPA). In some embodiments, the n-3 FA comprises DHA and EPA. EPA and DHA may optionally be present in a ratio of about 4:1 to about 1:4 (e.g., about 1:1). In yet other embodiments, the FA may further comprise arachidonic acid (ARA) or medium-chain fatty acids (MCFA). In some embodiments, the DG or TG (or emulsion) further comprises one or more special degradation-promoting mediators (SPMs), which are oxygenated metabolites mainly derived from AA, EPA, DPA, and DHA. These include lipoxins, (neuro)protectins, resolvins, and malecins, which may have potent anti-apoptotic, anti-inflammatory, and immunomodulatory effects at concentrations ranging from nanomolars to picomolars.

[0009] In various embodiments, the emulsion contains about 10% to about 30% by weight of TG oil and / or DG oil in the total composition, along with one or more emulsifiers. For example, the emulsion may contain about 15% to about 30% by weight of DG oil, or about 15% to about 25% by weight of DG oil (e.g., about 20% DG oil), in the total composition, along with one or more emulsifiers.

[0010] In various embodiments, subjects (e.g., neonates who have experienced or are at risk of HIE) receive the emulsion as one or more bolus injections or infusions, or via a nasogastric (NG) tube. In some embodiments, subjects may receive at least two, and up to six, doses of the emulsion. In various embodiments, the emulsion may be administered over a period of one day to about one week, and may be administered at least once a day (e.g., almost daily).

[0011] As an exemplary embodiment, the Disclosure provides a method for protecting against brain injury associated with HIE in neonates, the method comprising administering an intravenous injection of n-3FA DG or TG emulsion to a pregnant mother carrying a child at risk of HIE, either prenatally or during labor. Postnatally, the neonate may optionally be further treated with HT therapy and / or DG or TG emulsion therapy. In some embodiments, once HIE is anticipated or at high risk, the DG or TG emulsion is administered intravenously to the mother prenatally or during labor.

[0012] In other exemplary embodiments, the method for neuroprotection includes administering an n-3FA DG emulsion to a neonatal subject in need within approximately 12 hours of delivery, or within approximately 10 hours of delivery, or within approximately 8 or 6 hours (or less) of delivery, and treating the neonatal subject with an HT regimen. The emulsion may be administered before, during, and / or after the HT regimen. For example, at least the first dose of the emulsion may be administered within approximately 6 hours of delivery, or within approximately 4 hours of delivery, or within approximately 2 hours of delivery, thereby providing neuroprotection while the neonatal subject is being transported to initiate HT. This emulsion is administered via a nasogastric (NG) tube or intravenously. According to these embodiments, HT may be initiated later than generally desired, and still provide unexpected therapeutic effects. In yet another embodiment, HT is initiated first, followed by the administration of the n-3FA TG or DG emulsion.

[0013] In other embodiments, the Disclosure provides pharmaceutical compositions that can be used in the various methods described herein. In various embodiments, the pharmaceutical composition comprises an effective amount of n-3FA DG emulsion, wherein the DG comprises at least about 50% EPA and DHA, 1% to about 40% arachidonic acid (ARA) and / or medium-chain fatty acids (MCFA) (relative to the total FA content by weight), and one or more emulsifiers.

[0014] In some embodiments, the emulsion contains about 10% to about 30% by weight of diglyceride oil. In some embodiments, the emulsion contains about 15% to about 25% by weight of diglyceride oil. The composition further comprises one or more emulsifiers to obtain the desired physical properties. In various embodiments, the emulsifier may include one or more phospholipid emulsifiers, phosphoglyceride emulsifiers, and medium-chain and / or long-chain fatty acid emulsifiers. The phosphoglyceride emulsifier may be selected from phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine, and phosphatidic acid. The medium-chain or long-chain FA as a co-emulsifier may be selected from lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, and linolenic acid. An exemplary co-emulsifier is sodium oleate.

[0015] In various embodiments, the composition optionally comprises one or more polyols, such as glycerol. For example, the composition may contain about 2% to about 10% by weight of glycerol. In some embodiments, the composition further comprises one or more antioxidants, such as one or more of α-tocopherol, β-tocopherol, γ-tocopherol, and ascorbyl esters. In some embodiments, the composition further comprises a metal chelating agent, which is optionally EDTA or EGTA.

[0016] Further aspects and embodiments of this disclosure are described herein by further detail. [Brief explanation of the drawing]

[0017] [Figure 1A]Effects of hypothermia (HT) and tri-DHA on infarct volume: Infarct volume (A) and representative TTC-stained cerebral sections (B) of mice treated with normal body temperature (NT) + saline (n=21), HT + saline (n=20), tri-DHA (n=21), or HT + tri-DHA (n=11) starting immediately after hypoxic-ischemic (HI) injury (0 hours) (infarct volume %): NT + saline -33.2±4.8, HT + saline -14.9±4.8, 0-hour tri-DHA -14.9±4.5, 0-hour HT + tri-DHA -15.0±7.0); representative Nissl-stained coronal sections (C) of mice treated with NT + saline, HT + saline, or HT + tri-DHA starting immediately after HI injury (0 hours). Values ​​are mean ± SEM. *p<0.05, compared to the NT + saline group. [Figure 1B] Effects of hypothermia (HT) and tri-DHA on infarct volume: Infarct volume (A) and representative TTC-stained cerebral sections (B) of mice treated with normal body temperature (NT) + saline (n=21), HT + saline (n=20), tri-DHA (n=21), or HT + tri-DHA (n=11) starting immediately after hypoxic-ischemic (HI) injury (0 hours) (infarct volume %): NT + saline -33.2±4.8, HT + saline -14.9±4.8, 0-hour tri-DHA -14.9±4.5, 0-hour HT + tri-DHA -15.0±7.0); representative Nissl-stained coronal sections (C) of mice treated with NT + saline, HT + saline, or HT + tri-DHA starting immediately after HI injury (0 hours). Values ​​are mean ± SEM. *p<0.05, compared to the NT + saline group. [Figure 1C]Effects of hypothermia (HT) and tri-DHA on infarct volume: Infarct volume (A) and representative TTC-stained cerebral sections (B) of mice treated with normal body temperature (NT) + saline (n=21), HT + saline (n=20), tri-DHA (n=21), or HT + tri-DHA (n=11) starting immediately after hypoxic-ischemic (HI) injury (0 hours) (infarct volume %): NT + saline -33.2±4.8, HT + saline -14.9±4.8, 0-hour tri-DHA -14.9±4.5, 0-hour HT + tri-DHA -15.0±7.0); representative Nissl-stained coronal sections (C) of mice treated with NT + saline, HT + saline, or HT + tri-DHA starting immediately after HI injury (0 hours). Values ​​are mean ± SEM. *p<0.05, compared to the NT + saline group. [Figure 2A] Therapeutic scope of hypothermia (HT) and tri-DHA: Infarct volume (A) and representative TTC-stained cerebral sections (B) of mice treated with normal body temperature (NT) + saline (n=22), HT + saline (n=22), or HT + tri-DHA (n=21), starting 2 hours after hypoxic-ischemic (HI) injury (Infarct volume %): NT + saline -31.4±4.1, 2-hour delayed HT + saline -18.8±4.6, 2-hour delayed HT + tri-DH A -12.7±4.0); Infarct volume (C) and representative TTC-stained cerebral sections (D) of mice treated with normal body temperature (NT) + saline (n=19), HT + saline (n=23), or HT + tri-DHA (n=10) starting 4 hours after hypoxic-ischemic (HI) injury (infarct volume %): NT + saline -30.7±5.0, 4-hour delayed HT + saline -31.3±5.6, 4-hour delayed HT + tri-DHA -41.3±5.5. Values ​​are mean ± SEM. *p<0.05, **p<0.01, compared to the NT + saline group. [Figure 2B]Therapeutic scope of hypothermia (HT) and tri-DHA: Infarct volume (A) and representative TTC-stained cerebral sections (B) of mice treated with normal body temperature (NT) + saline (n=22), HT + saline (n=22), or HT + tri-DHA (n=21), starting 2 hours after hypoxic-ischemic (HI) injury (Infarct volume %): NT + saline -31.4±4.1, 2-hour delayed HT + saline -18.8±4.6, 2-hour delayed HT + tri-DH A -12.7±4.0); Infarct volume (C) and representative TTC-stained cerebral sections (D) of mice treated with normal body temperature (NT) + saline (n=19), HT + saline (n=23), or HT + tri-DHA (n=10) starting 4 hours after hypoxic-ischemic (HI) injury (infarct volume %): NT + saline -30.7±5.0, 4-hour delayed HT + saline -31.3±5.6, 4-hour delayed HT + tri-DHA -41.3±5.5. Values ​​are mean ± SEM. *p<0.05, **p<0.01, compared to the NT + saline group. [Figure 2C] Therapeutic scope of hypothermia (HT) and tri-DHA: Infarct volume (A) and representative TTC-stained cerebral sections (B) of mice treated with normal body temperature (NT) + saline (n=22), HT + saline (n=22), or HT + tri-DHA (n=21), starting 2 hours after hypoxic-ischemic (HI) injury (Infarct volume %): NT + saline -31.4±4.1, 2-hour delayed HT + saline -18.8±4.6, 2-hour delayed HT + tri-DH A -12.7±4.0); Infarct volume (C) and representative TTC-stained cerebral sections (D) of mice treated with normal body temperature (NT) + saline (n=19), HT + saline (n=23), or HT + tri-DHA (n=10) starting 4 hours after hypoxic-ischemic (HI) injury (infarct volume %): NT + saline -30.7±5.0, 4-hour delayed HT + saline -31.3±5.6, 4-hour delayed HT + tri-DHA -41.3±5.5. Values ​​are mean ± SEM. *p<0.05, **p<0.01, compared to the NT + saline group. [Figure 2D]Therapeutic scope of hypothermia (HT) and tri-DHA: Infarct volume (A) and representative TTC-stained cerebral sections (B) of mice treated with normal body temperature (NT) + saline (n=22), HT + saline (n=22), or HT + tri-DHA (n=21), starting 2 hours after hypoxic-ischemic (HI) injury (Infarct volume %): NT + saline -31.4±4.1, 2-hour delayed HT + saline -18.8±4.6, 2-hour delayed HT + tri-DH A -12.7±4.0); Infarct volume (C) and representative TTC-stained cerebral sections (D) of mice treated with normal body temperature (NT) + saline (n=19), HT + saline (n=23), or HT + tri-DHA (n=10) starting 4 hours after hypoxic-ischemic (HI) injury (infarct volume %): NT + saline -30.7±5.0, 4-hour delayed HT + saline -31.3±5.6, 4-hour delayed HT + tri-DHA -41.3±5.5. Values ​​are mean ± SEM. *p<0.05, **p<0.01, compared to the NT + saline group. [Figure 3] Infarct volume in neonatal mice (10 days old) that suffered hypoxic-ischemic (HI) injury and were treated with physiological saline, n-3 triglyceride (TG), and n-3 diglyceride (DG) emulsions as vehicles. n=15-17. Values ​​are mean values ​​with standard deviation. Dose = 0.375 mg / g (body weight). [Figure 4] Infarct volume (n=15-17) in neonatal mice (10 days old) treated with hypoxic-ischemic (HI) injury and either saline solution or DHA (PD1)-derived neuroprotectin at concentrations of 10 or 20 ng per mouse, or DPA-derived neuroprotectin (PD1 n-3 DPA) at a concentration of 10 ng per mouse for comparison. Values ​​are mean values ​​with standard deviation. [Modes for carrying out the invention]

[0018] In various aspects and embodiments, the present invention provides pharmaceutical compositions and methods for protecting against brain injury associated with hypoxic-ischemic encephalopathy (HIE). The compositions and methods use omega-3 fatty acid (n-3 FA) diglycerides (DG) and / or triglycerides (TG) formulated in an emulsion.

[0019] In accordance with various aspects and embodiments, the present disclosure provides compositions and methods for preventing or reducing brain injury caused by oxygen deprivation and / or blood flow restriction during the prenatal, intrapartum, or postnatal periods. Such conditions are often clinically described as (neonatal) hypoxic-ischemic encephalopathy (HIE), which includes neonatal encephalopathy with birth asphyxia, intrapartum asphyxia, and perinatal asphyxia. HIE can cause various types of tissue damage and can result in long-term disabilities such as cerebral palsy, cognitive impairment, epilepsy, hearing impairment, and visual impairment.

[0020] Causes of HIE during pregnancy (i.e., where the neonate is at risk of HIE) include preeclampsia, eclampsia, gestational diabetes, and infections. Other conditions during pregnancy or intrapartum where the neonate is at risk of HIE include placental abruption, placenta previa, placental insufficiency, uterine rupture, and umbilical cord complications. Umbilical cord complications include umbilical cord compression, which can occur, for example, during a prolonged labor. Changes in fetal heart rate or uterine contractions before delivery can be predictive factors for HIE. Premature neonates in the neonatal period are particularly at high risk of HIE because their lungs may be underdeveloped. Generally, symptoms indicating the risk of HIE in neonates include respiratory distress, jaundice, and neonatal hypoglycemia. Signs of HIE include respiratory disorders, feeding disorders, absence of reflex nerves, seizures, and decreased level of consciousness.

[0021] Neonatal high-intensity engorgement (HIE) or the risk of HIE can be diagnosed or assessed using the Apgar score. The five criteria assessed by the Apgar score are: (1) appearance (i.e., skin color / shade); (2) pulse; (3) grimace (i.e., response to stimuli); (4) activity (i.e., muscle tone / activity level); and (5) respiration. Generally, each of the five criteria is scored as 0, 1, or 2 (2 being the highest), and the total score is calculated by adding up the values ​​of 5. Scores of 0-3 are considered important, especially in babies born at or near full term. Scores of 4-6, especially at 5 minutes, are considered below normal and may indicate a risk of HIE, potentially requiring medical intervention. A score of 7+ is considered normal.

[0022] Alternatively, the risk of HIE can be assessed by collecting umbilical cord blood immediately after birth. Blood pH and base deficiencies (BD) are known means of assessing whether an ischemic event has occurred. Other predictors of HIE include brain-specific creatine kinase (CK-BB), protein S-100B, neuron-specific endolase, and other inflammatory markers, such as interleukins, which are known serum markers of brain injury. (Nagdyman N., et al. Early biochemical indicators of hypoxic-ischemic encephalopathy after birth asphyxia. Pediatr Res. 2001 Apr;49(4):502-6.) Other imaging and neurophysiological tests can also be used to determine early risk and provide long-term prognosis. These include amplitude-integrated electroencephalography (EEG), T1-weighted and T2-weighted MRI, thalamic magnetic resonance spectroscopy (MRS), and deep gray matter lactate / N-acetylaspartate (Lac / NAA) peak / area ratio. (Pang R., et al., Proton Magnetic Resonance Spectroscopy Lactate / N-Acetylaspartate within 48 h Predicts Cell Death Following Varied Neuroprotective Interventions in a Piglet Model of Hypoxia-Ischemia With and Without Inflammation-Sensitization. Front Neurol. 2020;11:883.)

[0023] In several embodiments, this disclosure provides pharmaceutical compositions and methods using stable omega-3 DG or TG oil-in-water emulsions for acute treatment. In various embodiments, the DG or TG emulsions contain about 50% to about 100% omega-3 fatty acids (relative to the total weight of fatty acids), including DHA and EPA, and optionally DPA. In some embodiments, the total fatty acids further include ARA or MCFA. DG emulsions are suitable for parenteral delivery, such as via intravenous (iv) routes, and the physical properties of DG and TG emulsions facilitate rapid delivery of omega-3 fatty acids to damaged brain tissue. In some embodiments, the DG or TG emulsion generally constitutes about 10% to about 30% by weight of the composition; that is, about 10% to about 30g of DG oil or TG oil per 100mL of emulsion. Exemplary compositions of the emulsions are described elsewhere in this specification.

[0024] Administration of the emulsions described herein (e.g., n-3 FA DG emulsion) may provide synergistic protection with therapeutic hypothermia (HT) or may act as an alternative to HT. HT is currently an accepted treatment for HIE. HT is a procedure used to slow the damaging process associated with HIE. HT involves cooling the infant to approximately 33.5–34.5°C for approximately 72 hours. Ideally, it should be initiated postnatally or within approximately 6 hours of an oxygen-deficient event. During HT, a cooling cap may be used to selectively cool the brain, or a cooling blanket may be used to cool the whole body. Vital signs such as respiration, oxygenation, heart rate, and electroencephalogram activity are monitored during the procedure. After HT, the body should be slowly rewarmed at a rate of approximately 0.5°C per hour (over at least 4 hours).

[0025] This disclosure investigates whether simultaneous treatment with HT and triglyceride-DHA (tri-DHA) in a neonatal mouse model achieves a synergistic effect in protecting the brain from HI injury. HT initiated immediately after HI injury was observed to reduce stroke volume (approximately 50%) similarly to tri-DHA treatment. These results indicate that HT provides comparable neuroprotection against HI injury compared to tri-DHA treatment. HT is only available in tertiary care centers, requires thorough monitoring, and can have adverse effects. In contrast, tri-DHA treatment may be advantageous as a viable and effective alternative strategy for neonates immediately after HI injury, eliminating the need to transfer neonates from hospitals to specialized facilities. Therefore, in some embodiments, subjects do not receive HT therapy, and TG or DG emulsion is provided as an alternative therapy. In other embodiments, TG or DG emulsion is provided to subjects before HT, for example, during HT preparation, or before or during transport to a specialized facility where HT can be administered. DG emulsion provides a remarkably more effective treatment than TG, and given its high level of efficacy, it results in improved efficacy compared to HT, or a synergistic effect with HT. In other embodiments, TG or DG emulsion is administered first during or after HT.

[0026] While some of the mechanistic pathways of HIE are similar to those of adult stroke, the pathobiology of HIE injury is thought to differ from that of adult stroke. In fact, therapies designed to improve brain injury in adults may worsen neonatal outcomes, possibly by promoting apoptosis.

[0027] For example, myelination is still occurring in the neonatal brain, and the water content of the neonatal brain is higher than that of the mature brain, so the appearance and time course of injury in the neonatal brain differ from that of the adult brain. Mechanisms of cell death have been shown to differ in the developing brain compared to the adult brain (Zhu C, et al. The influence of age on apoptotic and other mechanisms of cell death after cerebral hypoxia-ischemia. Cell Death Differ. 2005, 12, 162-176). Mechanisms of mitochondrial permeabilization are age-dependent, with cyclophilin D being important in the adult brain, but Bax-related mechanisms dominating in the immature brain (Wang X, et al. Developmental shift of cyclophilin D contribution to hypoxic-ischemic brain injury. J. Neurosci. 2009, 29, 2588-2596). Compared to adults, immature brains express more pro-apoptotic proteins (including Bax, caspase-2, -3, -8, and -9), and apoptosis occurs after mitochondrial outer membrane permeabilization (MOMP).A pathway dependent on apoptosis-inducing factor (AIF) (Zhu C, et al. Involvement of apoptosis-inducing factor in neuronal death after hypoxia-ischemia in the neonatal rat brain. J. Neurochem. 2003, 86, 306-317), and caspases appear to be activated more strongly in immature brains than in adult brains (Hu BR, et al. Involvement of caspase-3 in cell death after hypoxia-ischemia declines during brain maturation. J. Cereb. Blood Flow Metab. 2000, 20, 1294-1300), and it has been proposed that mitochondrial permeability signals a point of no return in hypoxic-ischemic injury of immature brains (Hagberg H. Mitochondrial impairment in the developing brain after hypoxia-ischemia. J. Bioenerg. Biomembr. 2004, 36, 369-373). In immature brains, cyclophilin D gene deficiency exacerbates hypoxic-ischemic injury rather than mitochondrial injury compared to adult mice (Wang et al., 2009; Schinzel AC, et al. Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia. Proc. Natl. Acad. Sci. USA 2005, 102, 12005-12010).Instead, BAX-inhibiting peptides (Wang X. et al. Neuroprotective effect of Bax-inhibiting peptide on neonatal brain injury. 2010, Stroke 41, 2050-2055) and BAX deficiency (Gibson ME, et al. BAX contributes to apoptotic-like death following neonatal hypoxia-ischemia: evidence for distinct apoptosis pathways. Mol. Med. 2001, 7, 644-655) substantially protect the immature brains of neonatal mice.

[0028] Furthermore, stroke triggers a powerful inflammatory response in both adult and neonatal brains. Experimental evidence from adult models has shown that brain injury rapidly activates microglia, leading to increased phagocytic activity and altered production of cytokines and reactive oxygen species metabolites (Hanisch UK. Microglia as a source and target of cytokines. 2002, Glia 40, 140-155), a feature also well-documented in neonatal hypoxic-ischemic (HI) injury (Hedtjarn M, et al. Inflammatory gene profiling in the developing mouse brain after hypoxia-ischemia. J. Cereb. Blood Flow Metab. 2004, 24, 1333-1351). However, compared to adults, microglial activation in neonates is far more rapid after ischemic injury. In adult brains, peripheral immune cell infiltration into the brain after stroke injury also contributes significantly (Iadecola C and Anrather J. The immunology of stroke: from mechanisms to (translation.2011, Nat.Med.17,796-808). In contrast, peripheral cell infiltration is rarely observed in acute cases after neonatal stroke (Denker SP, et al. Macrophages are comprised of resident brain microglia not infiltrating peripheral monocytes acutely after neonatal stroke. J.Neurochem.2007,100,893-904). Therefore, these findings suggest differences in the central nervous system immune response to injury between neonates and adults.

[0029] Furthermore, the blood-brain barrier in neonates after acute ischemic brain injury is remarkably intact compared to adult animals, partly due to differential expression of basal layer and tight junction proteins, as well as neutrophil behavior (Fernandez-Lopez D, et al. Blood-brain barrier permeability is increased after acute adult stroke but not neonatal stroke in the rat. J Neurosci. 2012 7 11;32(28):9588-600).

[0030] Therefore, in various embodiments, the subject is prenatal or during labor, there is a risk of HIE (i.e., HIE is expected), and the n-3FA DG or TG emulsion is administered to the pregnant mother, for example, intravenously. For example, the n-3 FA DG or TG emulsion may be administered intravenously to the mother when pre-eclampsia or other pregnancy conditions associated with HIE risk are detected (as already described). In some embodiments, the emulsion is administered prenatally or during labor, including prolonged labor, or when it is determined that the newborn is at risk of HIE due to umbilical cord compression. As described in more detail herein, the emulsion may be administered intravenously as one or more bolus doses, by sequential infusions, or as a combination of one or more bolus loading doses followed by one or more additional doses. For example, intravenous doses may be administered as a bolus (over 0 to 60 minutes), by infusion (over 60 minutes to 24 hours), or as a combination of one or more bolus loading doses followed by one or more additional doses by infusion. Alternatively, the emulsion may be administered via an NG tube.

[0031] In other embodiments, the subject is a neonat (i.e., a newborn) suspected of having HIE. In various embodiments, the neonat is premature or full-term. The n-3FA DG or TG emulsion is administered to the neonat within approximately 12 hours of delivery, or within approximately 10 hours of delivery, or within approximately 8 hours of delivery, or within approximately 6 hours of delivery, or within approximately 4 hours of delivery, or within approximately 2 hours of delivery. For delivery to neonates, the emulsion may be administered via an NG tube or intravenously as a bolus dose and / or continuous infusion.

[0032] In various embodiments, neonates are further treated with HT either before, during, or after administration of n-3FA DG or TG. HT should generally be initiated as early as possible, such as within approximately 6 hours or 4 hours after delivery. However, in some embodiments, HT is initiated within approximately 12 hours, 10 hours, or 8 hours after delivery. In some embodiments, particularly with the administration of DG or TG emulsion, the scope over which HT provides benefit in avoiding brain injury and long-term and / or lifelong HIE complications can be extended. Therefore, in such embodiments, HT is initiated approximately 6 hours, 8 hours, 10 hours, or 12 hours after delivery, which may be due to delays in detecting HIE or transferring the neonatal patient from the hospital to a tertiary care facility equipped for HT.

[0033] In various embodiments, after treatment with DG or TG emulsion and / or HT, neonatal patients may be further treated with parenteral nutrition containing omega-3 fatty acids. This may include infusion of approximately 1 g / kg / day of TG emulsion, which may be prepared from approximately 10% fish oil (e.g., approximately 25% to approximately 60% EPA and DHA). Such emulsions are commercially available under the name Omegaven. Omegaven is an intravenous lipid emulsion that provides calories and anti-inflammatory fatty acids to pediatric patients with parenteral nutrition-associated cholestasis, i.e., PNAC. Such parenteral nutrition may be provided for several weeks to several months, for example, 2 weeks to approximately 20 weeks, or approximately 4 weeks to approximately 16 weeks.

[0034] In various embodiments, the present invention delivers n-3 FAs to cells as stable DG or TG emulsions. The term "n-3 FA" refers to polyunsaturated FAs in which one of the carbon-carbon double bonds is between the third and fourth carbon atoms from the distal end of the hydrocarbon chain. An example of an n-3 FA is α-linolenic acid (18:3n-3; α-ALA; Δ 3、6、9 ), eicosapentaenoic acid (20:5n-3; EPA; Δ 5、8、11、14、17 ), docosahexaenoic acid (22:6n-3; DHA; Δ 4、7、10、13、16、19 ) and docosapentaenoic acid (22:5n-3; DPA; Δ 7、10、13、16、19 Examples include n-3 FAs having at least 20 carbon atoms are called "long-chain n-3 FAs". Sources of n-3 FAs may be derived from any suitable source such as fish oil, algal oil, and other oils, or they may be synthesized.

[0035] DG is composed of two FAs esterified to trihydric alcohol glycerol. An example of a method for synthesizing the DG molecule is by lipase-catalyzed glycerol decomposition (i.e., transesterification) using n-3 long-chain FAs. An exemplary process for preparing DG oil is described in International Publication No. 2019 / 234057, which is incorporated herein by reference in its entirety. As used herein, DG oil refers to an oil in which at least about 75% of the glycerides are diacylglycerides. However, in some embodiments, at least about 80%, or at least about 90% (e.g., about 100%) of the glycerides are diacylglycerides. Similarly, when a TG emulsion is used, TG oil refers to an oil in which at least about 75% of the glycerides are triacylglycerides. However, in some embodiments, at least about 80%, or at least about 90% (e.g., about 100%) of the glycerides are triacylglycerides.

[0036] According to the present invention, the fatty acids (FAs) in DG or TG may be primarily n-3 FAs. In various embodiments, DG or TG contains at least about 50% n-3 FAs (by weight of total fatty acids), or at least about 75% n-3 FAs, or at least about 90% n-3 FAs, or about 100% n-3 FAs. In some embodiments, the n-3 FAs are long-chain n-3 FAs comprising one or more of DHA, EPA, and DPA. Interestingly, neuroprotective D1 derived from DPA is neuroprotective at lower concentrations than neuroprotective D1 derived from DHA (measured by reduction in infarct size after hypoxic-ischemic brain injury) (Figure 4).

[0037] In various embodiments, n-3 FA contains DHA. In some embodiments, n-3 FA is at least about 50% DHA, or at least about 60% DHA, or at least about 75% DHA, or at least about 90% DHA. In some embodiments, n-3 FA contains EPA. For example, n-3 FA may be at least about 50% EPA, or at least about 60% EPA, or at least about 75% EPA, or at least about 90% EPA. In some embodiments, n-3 FA contains DHA and EPA. For example, FA may contain at least about 50% EPA and DHA, or at least about 60% EPA and DHA, or at least about 70% EPA and DHA, or at least about 80% EPA and DHA, or at least about 90% EPA and DHA. EPA and DHA may be present in a ratio of approximately 4:1 to approximately 1:4, for example, approximately 3:1 to approximately 1:3, or approximately 2:1 to approximately 1:2 (for example, approximately 1:1). In various embodiments, the DG molecule is one or more of 1,2-DG or 1,3-DG. In some embodiments, DG is primarily 1,3-DG.

[0038] In further embodiments, the fatty acids further comprise ARA, for example, about 1% to about 40% ARA (by weight of total fatty acids in the glyceride), or in some embodiments, about 1% to about 30%, or about 5% to about 25%, or about 5% to about 20%, or about 10% to about 20% ARA. ARA are essential n-6 fatty acids important for infant brain development. In these or other embodiments, the emulsion further comprises MCFA as free FA, or esterified as TG and / or DG. MCFA-rich TG enhances the efficiency of omega-3 fatty acids to cell membranes. In some embodiments, MCFA is present in the range of about 1% to about 20% by weight of fatty acids in the TG and / or DG emulsion. In some embodiments, the composition comprises medium-chain triglycerides (MCTs) as described in U.S. Patent No. 9,675,572, which is incorporated herein by reference in whole.

[0039] In some embodiments, DG or TG (or emulsions thereof) contains one or more SPMs. SPMs are oxygenated metabolites mainly derived from AA, EPA, DPA, and DHA. These include lipoxins, (neuro)protectins, resolvins, and malecins, which may have potent anti-apoptotic, anti-inflammatory, and immunomodulatory effects at concentrations ranging from nanomolar to picomolar. SPMs are produced by dioxygen-dependent oxidation from n-3 FA and n-6 ​​FA precursors. Examples of SPMs include specific AA-derived lipoxins (LXA4 and LXB4), EPA-derived E-series resolvins (RvE1-3), DHA-derived D-series resolvins (RvD1-6), protectins / neuroprotectins (PD1 / NPD1 and PDX), malecins (MaR1 and MaR2), and DPA-derived 13-series resolvins (RvT1-4). SPMs can function as immunosolvents.

[0040] In some embodiments, DG or TG (or its emulsion) includes at least one SPM derived from EPA, such as resolvin E1, resolvin E2, and resolvin E3. In some embodiments, DG or TG (or its emulsion) includes at least one SPM derived from DHA, such as resolvin D1, resolvin D2, resolvin D3, resolvin D4, resolvin D5, resolvin D6, or stereoisomers thereof. In some embodiments, DG or TG (or its emulsion) includes at least one SPM derived from DPA, such as resolvin T1, resolvin T2, resolvin T3, resolvin T4, resolvin 1n-3DPA, resolvin 2n-3DPA, resolvin 5n-3DPA, protectin 1n-3DPA, protectin 2n-3DPA, malecin 1n-3DPA, malecin 2n-3DPA, and malecin 3n-3DPA. In some embodiments, DG or TG (or its emulsion) comprises at least one bioactive lipid derived from arachidonic acid (AA), such as lipoxin A4, lipoxin B4, or their stereoisomers.

[0041] In various embodiments, the emulsion contains about 10% to about 30% by weight of TG oil and / or DG oil per weight of the total composition. For example, the emulsion may contain about 15% to about 25% by weight (e.g., about 15%, about 20%, or about 25%) of DG oil per total composition. Other components of the emulsion (e.g., emulsifiers) are described elsewhere in this specification.

[0042] In various embodiments, subjects (e.g., neonatal subjects who have experienced or are at risk of HIE) are administered the emulsion as a single bolus injection or infusion, or via NG. For example, a subject may receive at least two, and up to six (e.g., two to four) bolus injections or infusions of the emulsion. In various embodiments, bolus injections or infusions are administered at a frequency of approximately once every 12 hours or less. However, in various embodiments, administration can be made at intervals independently selected from approximately 1 hour, approximately 2 hours, approximately 3 hours, approximately 6 hours, approximately 12 hours, or approximately 24 hours. In various embodiments, the emulsion may be administered over a period of 1 day to approximately 1 week, and may be administered almost daily. In various embodiments, the bolus dose is approximately 0.05 g to approximately 5 g of emulsified DG or TG per kg of body weight, or approximately 0.5 g to approximately 5 g per kg of body weight. For example, the bolus dose may be approximately 2 g to approximately 4 g of emulsified DG or TG per kg of body weight.

[0043] As an exemplary embodiment, this disclosure provides a method for protecting against brain injury associated with hypoxic-ischemic encephalopathy (HIE) in neonates, the method comprising administering an intravenous injection of n-3FA DG or TG emulsion to a pregnant mother carrying a child at risk of HIE, either prenatally or at delivery. Postnatally, the neonate may optionally be further treated with HT therapy and / or DG or TG therapy. In some embodiments, once HIE is anticipated or at significant risk, the emulsion is administered intravenously to the mother prenatally or at delivery. The administration and composition of the emulsion are as described elsewhere in this specification. The neonate may be premature or full-term.

[0044] In some embodiments, a further dose of n-3DG or TG emulsion is administered to the neonatal infant within approximately 12 hours or 10 hours of delivery (i.e., birth), or within approximately 6 hours or 8 hours of delivery, or within approximately 4 hours of delivery, or within approximately 2 hours of delivery. The timing of postpartum HT is generally as early as possible, as previously stated. In various embodiments, the neonatal infant receives a single bolus injection or infusion of the emulsion (or via the NG route). However, in some embodiments, the neonatal infant receives at least two, and up to six (e.g., 2-4) bolus injections or infusions of the emulsion. These are generally administered over approximately one week and may be administered almost daily via intravenous and / or NG routes.

[0045] In other exemplary embodiments, the method for neuroprotection includes administering an n-3 DG or TG emulsion to the neonatal subject in need within approximately 10 hours of delivery, and treating the neonatal subject with an HT regimen. The n-3 DG or TG emulsion is initially administered before, during, or after HT. For example, at least the first dose of the emulsion may be administered within approximately 6 hours of delivery, or within approximately 4 hours of delivery, or within approximately 2 hours of delivery, thereby providing neuroprotection while the neonatal subject is being transported to a specialized facility to initiate HT. The DG or TG emulsion is administered via a nasogastric (NG) tube or intravenously, as a bolus and / or continuous infusion, as already described.

[0046] According to these embodiments, HT may be initiated later than generally desired, and still provide unexpected therapeutic effects. For example, in some embodiments, the dose of DG or TG emulsion is administered within about 4 hours of delivery, and HT is initiated within about 10 hours of delivery. In some embodiments, the dose of DG or TG emulsion is administered within about 4 hours of delivery, and HT is initiated within about 8 hours or about 6 hours of delivery.

[0047] In further embodiments, the dose of the DG or TG emulsion is administered within approximately two hours (or within approximately one hour) of delivery, and HT is initiated approximately six hours, eight hours, ten hours, or twelve hours after delivery. In various embodiments, the subject receives a single bolus injection or infusion of the emulsion, while in other embodiments, the subject receives at least two and up to six (e.g., two to four) bolus injections or infusions of the emulsion. These may generally be administered over a period of approximately one day to one week, for example, almost daily.

[0048] In other embodiments, the Disclosure provides pharmaceutical compositions that can be used in the various methods described herein. In various embodiments, the pharmaceutical composition comprises an effective amount of n-3 DG or TG emulsion, where DG or TG comprises at least about 50% EPA and DHA, and 1% to about 40%, or 1% to about 30%, or 1% to about 20%, or 1% to about 10% ARA (relative to the total FA content by weight), and one or more emulsifiers. In some embodiments, DG or TG comprises about 5% to about 25% by weight of FA, or about 5% to about 20% by weight, or about 10% to about 20% by weight of ARA. In some embodiments, FA comprises at least about 60% EPA and DHA, or at least about 70% EPA and DHA, or at least about 80% EPA and DHA. In some embodiments, the EPA:DHA ratio is about 4:1 to about 1:4, or about 3:1 to about 1:3, or about 2:1 to about 1:2, and optionally about 1:1. Generally, the composition contains at least about 75% DG or TG relative to the total of monoacylglycerides, diacylglycerides, and triacylglycerides.

[0049] In some embodiments, the fatty acids further comprise DPA and / or MCFA, either as free FA or esterified as DG or TG. In various embodiments, the MCFA constitutes about 1% to about 20% (relative to the total weight of FA) of the fatty acids in the diglyceride emulsion. In some embodiments, the emulsion contains about 10% to about 30% by weight of DG or TG oil. In some embodiments, the emulsion contains about 15% to about 25% by weight (e.g., about 15%, about 20%, or about 25%) of DG or TG oil.

[0050] According to the compositions and methods described herein, the compositions are stable emulsions that can be stored in a stable form for use in emergencies. The emulsions described herein are substantially stable for at least 6 months or at least 1 year at 4°C. In various embodiments, the emulsion is stable for more than about 1 year (e.g., about 18 months or about 2 years) at 4°C, or in some embodiments, at room temperature (i.e., about 22°C). The compositions are suitable for delivery via parenteral delivery routes, such as intravenous or intra-arterial delivery, or via NG routes. Furthermore, in some embodiments, the physical properties of the emulsion facilitate the delivery of n-3 FA to brain tissue and / or uptake by brain tissue.

[0051] Emulsions are inherently unstable and therefore do not form spontaneously. Forming an emulsion requires energy input, such as through shaking, stirring, or homogenization. Over time, emulsions tend to revert to stable phases. However, nanoemulsions can be kinetically stable.

[0052] An emulsion is said to be stable if the size and dispersion of its droplets do not change substantially or significantly over a desired period (such as at least about six months). In other words, emulsion stability refers to the emulsion's ability to withstand changes in its properties over time. Instability in an emulsion can be observed, for example, as aggregation, creaming / settling, and coalescence. Aggregation occurs when there is an attractive force between droplets, causing them to form aggregates. Coalescence occurs when droplets combine to form larger droplets, resulting in an increase in the average droplet size over time. Emulsions may also undergo creaming, where droplets rise to the top of the emulsion, for example, due to buoyancy. Settling is the opposite phenomenon of creaming and is commonly observed in water-in-oil emulsions. Settling occurs when the dispersed phase is denser than the continuous phase, and gravity pulls the denser spheres towards the bottom of the emulsion. Like creaming, sedimentation follows Stokes' law. Other indicators of stability include the absence of an increase in the amount of free FA or oxidation products in the emulsion, or the absence of a decrease in tocopherol concentration over a long period (e.g., 6–24 months).

[0053] Emulsifiers are substances that stabilize emulsions by increasing their kinetic stability. Examples of emulsifiers include surfactants. Surfactants can enhance the kinetic stability of an emulsion so that the droplet size does not change significantly over time. Emulsifier stability can be evaluated in terms of the zeta potential, which indicates the repulsive force between droplets or particles. Emulsifiers are typically compounds having a polar or hydrophilic (i.e., water-soluble) part and a nonpolar (i.e., hydrophobic or lipophilic) part. Surfactants are a type of emulsifier that physically interacts with both oil and water, stabilizing the interface between oil and water droplets in a suspension.

[0054] In various embodiments, the emulsion has an average particle size of 200 nm or less and a negative zeta potential of about -40 mV or greater. In some embodiments, the average particle size of the emulsion is about 180 nm or less, or about 150 nm or less, or about 120 nm or less, or about 100 nm or less, or about 90 nm or less, or about 80 nm or less. In some embodiments, the average particle size is about 120 nm, or about 110 nm, or about 100 nm, and the polydispersity index is less than about 0.3 or less than about 0.2. In various embodiments, the zeta potential of the emulsion is at least as negative as about -45 mV, or at least as negative as about -50 mV, or at least as negative as about -55 mV, or at least as negative as about -60 mV. The emulsions according to these embodiments are stable, meaning that these parameters are maintained for at least 6 months, or at least 1 year in some embodiments. According to this disclosure, stability is measured by storage at about 5°C or room temperature (i.e., about 25°C).

[0055] Stable emulsions are suitable for intravenous administration, for example, to rapidly deliver n-3 FA to the brain. The lipid phase is generally about 10% to about 50% by weight of the composition. In some embodiments, the lipid phase is about 10% to about 40% by weight of the composition, or about 15% to about 40% by weight of the composition, or about 15% to about 30% by weight, or about 15% to about 25% by weight, or about 20% to about 25% by weight. For example, the lipid phase may be about 20% by weight of the composition, or about 25% by weight of the composition, or about 30% by weight of the composition. In some embodiments, at least about 10% by weight of the lipid phase is DG or TG, or at least about 15% by weight of the lipid phase is DG or TG, or at least about 20% by weight of the lipid phase is DG or TG, or about 30% by weight of the lipid phase is DG or TG, or at least about 40% by weight of the lipid phase is DG or TG, or at least about 50% of the lipid phase is DG or TG. In some embodiments, less emulsifier is required compared to a TG emulsion because DG itself provides emulsifying properties. For example, in some embodiments, the amount of emulsifier is about 0.5 to about 2% by weight of the composition, for example, about 1.2% by weight of the composition, or about 1% by weight, or about 0.8%, or about 0.6% by weight of the composition.

[0056] The polydispersity index (PDI) is a measure of the particle size distribution within a given sample. The PDI value ranges from 0.0 (for samples with a perfectly uniform particle size distribution) to 1.0 (for highly polydisperse samples with multiple particle size populations). For lipid-based carriers such as emulsions, a PDI of 0.3 is desirable, indicating a sufficiently uniform particle size distribution. In some embodiments, the PDI of an emulsion is less than approximately 0.3, for example, less than or equal to approximately 0.2, or less than or equal to approximately 0.1.

[0057] The composition further comprises one or more emulsifiers to obtain the desired physical properties. In various embodiments, the emulsifiers may include one or more phospholipid emulsifiers, phosphoglyceride emulsifiers, and medium-chain and / or long-chain fatty acid emulsifiers. In various embodiments, the composition comprises about 0.6% to about 10% by weight of emulsifiers, and optionally about 0.6% to about 7% by weight of emulsifiers, and optionally about 0.6% to about 5% by weight of emulsifiers, and optionally about 0.6% to about 3% by weight of emulsifiers.

[0058] In some embodiments, the emulsion comprises one or more phospholipid emulsifiers and / or one or more phosphoglyceride emulsifiers. The phosphoglyceride emulsifiers may be selected from phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine, and phosphatidic acid. In some embodiments, the composition comprises a phosphatidylcholine emulsifier.

[0059] In various embodiments, the ratio of phospholipid and / or phosphoglyceride emulsifier to DG or TG is about 1:4 to about 1:12, and in some embodiments, it is about 1:10 or less. In some embodiments, the emulsifier contains at least about 70% phosphatidylcholine, or at least about 80% phosphatidylcholine. For example, the emulsifier (including any co-emulsifier) ​​may contain about 60% to about 80% phosphatidylcholine.

[0060] The composition may further contain one or more medium-chain or long-chain fatty acids (FAs) as coemulsifiers. For example, the composition may contain long-chain FAs that are optionally selected from C16-C24 FAs and optionally C18 FAs. In some embodiments, the coemulsifier includes saturated FAs optionally selected from lauric acid, myristic acid, palmitic acid, and stearic acid. In some embodiments, the coemulsifier includes unsaturated FAs optionally selected from oleic acid or linolenic acid. This coemulsifier may optionally be added as an alkali metal salt containing sodium oleate. In exemplary embodiments, the coemulsifier is present in about 0.01% to 5% by weight of the total weight of the composition. For example, the coemulsifier may be present in about 0.01% to 2% by weight of the total weight of the composition, or about 0.01% to 1% by weight of the total weight of the composition, or about 0.01% to 0.05% by weight of the composition.

[0061] In various embodiments, the composition is substantially isotonic with human blood and optionally contains one or more polyols such as glycerol, sorbitol, xylitol, and / or glucose. For example, the composition may contain about 2% to about 10% by weight of the composition, or about 2% to about 7% by weight of the composition, glycerol.

[0062] In some embodiments, the composition comprises one or more antioxidants, such as one or more of α-tocopherol, β-tocopherol, γ-tocopherol, and ascorbyl esters. In exemplary embodiments, the antioxidant comprises α-tocopherol and / or ascorbyl ester, which is optionally ascorbyl palmitate.

[0063] In some embodiments, the composition includes a metal chelating agent, optionally EDTA or EGTA. For example, the emulsion may contain about 0.1 mM to about 5 mM, or about 0.1 mM to about 1 mM of EDTA or EGTA. For example, in some embodiments, the emulsion contains about 0.25 mM of EDTA.

[0064] In various embodiments, a stable emulsion may be prepared according to a process comprising: (1) preparing a mixture of water, glycerol, and EDTA at a temperature of about 50°C to about 80°C (e.g., about 60°C); (2) adding a phosphatidylcholine emulsifier (e.g., at least about 75% PC, which may be derived from egg yolk lecithin), a co-emulsifier (e.g., sodium oleate), and DG or TG oil; (3) homogenizing at a temperature of about 50°C to about 80°C (e.g., about 60°C); and (4) processing by microfluidizer. The pressure applied during this process may range from 300 to 2000 bar, and in some embodiments, it may range from about 500 to about 1000 bar, such as about 600 to about 900 bar. For example, the mixture may be processed through a microfluidizer at a pressure of about 800 bar at about 60°C. The emulsion may be processed for the length of time and under the conditions necessary to satisfy the target particle size.

[0065] In various embodiments, the pH of the composition is about 6 to about 9, and optionally about 6.5 to about 8.5, and optionally about 7 to about 8.

[0066] In various embodiments, the composition has a volume of about 500 mL or less, or about 300 mL or less, or about 50 mL or less, or about 25 mL or less. In various embodiments, the composition is contained in a pre-filled syringe having an injection volume of about 1 mL to about 50 mL, as needed.

[0067] The composition is generally delivered parenterally, such as intravenously or intra-arterially. In some embodiments, the composition is administered intranasally to allow for rapid delivery to the brain.

[0068] As used herein, the term "approximately" means within ±10% of the relevant figure.

[0069] Exemplary embodiments are described by the following examples. [Examples]

[0070] Example 1: Acute injection of omega-3 triglyceride emulsion provides neuroprotection similar to hypothermia therapy for cerebral hypoxic-ischemic injury in a neonatal mouse model. Hypoxic-ischemic (HI) brain injury is a serious event that frequently results in death or significant long-term neurological impairment in both neonates and adults (1-3). Currently, therapeutic hypothermia (HT) is the only established treatment for neonates with HI encephalopathy (4). Preclinical studies and small clinical trials have shown that HT may reduce the extent of neurological damage, lower mortality, and improve the recovery of neurological function (7, 8).

[0071] The main molecular mechanisms affected by HT include reduced free radical generation, limited blood-brain barrier disruption, reduced excitatory amino acid release, and attenuation of the cell-mediated inflammatory response to cerebral ischemia (9, 10). Furthermore, HT induces inhibition of neuronal apoptosis via both mitochondrial-based endogenous pathways and receptor-mediated exogenous pathways (11). However, HT remains a complex medical approach, requiring rigorous monitoring and only available in tertiary care centers (12). Pilot studies on HT in stroke have shown that adult patients have lower tolerance to cooling than neonates, and HT can also induce undesirable systemic effects such as shivering, immunosuppression, and pneumonia (13, 14). Combining HT with other treatments may aim not only to mitigate the adverse effects of HT but also to reach multiple molecular targets in the context of HI injury, thereby increasing the treatment time range and enhancing repair in long-term recovery (15).

[0072] As one of the major omega-3 polyunsaturated fatty acids in the brain, DHA is essential for brain development and function (16). DHA has been shown to reduce inflammation, excitotoxicity, and prevent brain volume reduction in various animal models of HI injury (17-19). This example investigates whether simultaneous treatment with HT and triglyceride DHA ("tri-DHA") emulsion achieves a synergistic effect in protecting the brain from HI injury. In this example, tri-DHA is a triglyceride oil in which >98% of the TG fatty acids are DHA. The inventors have confirmed the neuroprotective effect of HT on HI injury in previously described neonatal models (20, 22). These results indicate that tri-DHA provides comparable neuroprotection to HT, and that combining HT and tri-DHA emulsion does not provide an additional therapeutic effect on HI injury.

[0073] Materials and methods DHA TG oil was purchased from Nu-Chek Prep, Inc. (Elysian, MN). Egg yolk phosphatidylcholine was obtained from Avanti Polar-Lipids, Inc. (Alabaster, AL). Radiolabeled [ 3 [H]-Cholesteryl hexadecyl ether was purchased from PerkinElmer (Boston, MA) ([ 3 H]CEt)(NET 85900).

[0074] Tri-DHA emulsion (10 g TG weight / 100 mL emulsion) was prepared using DHA TG oil and egg yolk phospholipid (PL) by sonication as previously detailed (20). The amounts of TG and PL in the emulsion were analyzed using a commercially available kit (Wako Chemicals USA, Inc., Richmond, VA). The TG:PL mass ratio was 5.0 ± 1.0, which was similar to that of VLDL-sized particles. To prepare the radiolabeled emulsion, before sonication [ 3 [H]CEt was added to the TG-PL mixture (22).

[0075] Three-day-old C57BL / 6J neonatal mice, along with their mothers, were purchased from Jackson Laboratories (Bar Harbor). Both male and female mice were used in the experiment. As previously described (20), the inventors used the Rice-Vannuci method, which involves mild HI brain injury in ten-day-old (p10) mice. Briefly, HI brain injury was induced by permanent ligation of the right common carotid artery. After 1.5 hours of recovery, the mice were exposed to hypoxic injury (humidified 8% O2 / 92% N2, Tech Air Inc., NY) for 15 minutes at 37±0.3°C.

[0076] Immediately after HI injury, puppies were housed for 4 hours in temperature-controlled chambers with either hypertension (HT) or normothermia (NT), and their rectal temperatures reached 31–32°C or 37°C, respectively (23). Puppies placed in a circulating air chamber set to 27°C were observed to maintain a target rectal temperature of 31–32°C. In the NT group, puppies were placed in a chamber set to 32°C, based on the protocols of previous studies (20, 21). HI brain injury in neonatal mice is associated with a decrease in endogenous core body temperature (23). Therefore, puppies kept at 37°C during hypoxia were not subjected to hypothermia. Since the core body temperature of neonatal rodents may be affected by their distance from their mother (24), puppies were kept away from their mothers during the 4-hour HT or NT treatment period. Continuous temperature measurements were taken immediately after hypoxia (hour 0), followed by 1, 2, 3, and 4 hours during HT (probe type: RET-4; Physitemp Instruments, Clifton, NJ). The tri-DHA treatment (0.375g tri-DHA / kg body weight, intraperitoneal (ip), two injections at 1-hour intervals) followed the previous protocol (20, 21).

[0077] To investigate whether concomitant therapy with tri-DHA emulsion during hypertension (HT) enhances neuroprotection in HI (High Intraperitoneal) disorders, animals receiving HT were administered tri-DHA emulsion (0.375 g tri-DHA / kg body weight, two intraperitoneal injections) at the start of HT and one hour after the start of HT. NT (Nutritionally Transmitted) or HT control animals were injected with saline. After 4 hours of NT, control puppies were returned to their mothers. HT puppies were slowly rewarmed by increasing the room temperature at a rate of 0.1–0.2°C per minute until their rectal temperature reached 37°C, and then returned to their mothers.

[0078] Using radiolabeled tri-DHA emulsion, we determined whether hypertension (HT) affects the absorption and distribution of emulsion particles after intraperitoneal injection. Naive neonatal mice injected with radiolabeled tri-DHA emulsion (0.375 g tri-DHA / kg body weight, intraperitoneal, single injection) were immediately subjected to either HT (n=3) or NT (n=7) for 4 hours. The use of a single bolus injection to study emulsion distribution was based on previously established protocols (22, 25). Animals were sacrificed after 4 hours of HT or NT, and radioactivity in ascites, blood, organs, and tissues was examined. 3 The level of H]CEt was evaluated by measuring it.

[0079] Tissues and organs were homogenized using a Polytron Tissue Disruptor (Omni TH, Kenneswa, GA), and their radioactivity was measured by liquid scintillation spectroscopy (26). Samples were suspended and mixed in scintillation fluids (Ultima Gold scintillation fluid, PerkinElmer, Boston, MA) and assayed at 3H dpm using a PerkinElmer Tri-Carb liquid scintillation spectrometer 5110 TR. Tissue uptake was expressed as a percentage of the total recovered amount per organ for all organs analyzed.

[0080] The inventors determined the therapeutic range of HT after HI injury in mice: (1) 2-hour delayed HT - puppies placed with their mother for 2 hours after HI and then receiving HT; (2) 4-hour delayed HT - puppies placed with their mother for 4 hours after HI and then receiving HT. To investigate whether concomitant treatment of HT with tri-DHA emulsion extends the therapeutic range of HI injury, tri-DHA emulsion (0.375 g tri-DHA / kg body weight, 2 injections, intraperitoneal) was administered to animals that underwent HT (delayed by 2 or 4 hours after HI) at the start of HT and 1 hour after the start of HT. NT or HT control animals were administered physiological saline. After the treatment period, puppies from the NT or HT group were returned to their mothers as described above.

[0081] 24 hours after HI injury, animals were sacrificed and their brains were collected. Using a brain slicer matrix, 1 mm coronal slices were prepared. The slices were immersed in a PBS solution containing 2% triphenyltetrazolium chloride (TTC) at 37°C for 25 minutes. TTC is taken up by living mitochondria and turns red. Unstained areas that appear white are defined as infarct areas, while living areas appear red. Using Adobe Photoshop and the NIH Image J imaging application, the planar area of ​​the infarct on serial sections was summed to determine the volume of infarct tissue (mm3). Infarct area was expressed as a percentage of the total area of ​​the ipsilateral hemisphere (21). In another cohort of mice treated with HT or HT+tri-DHA immediately after HI, brain atrophy was detected by Nissl staining 7 days post-HI injury. The entire brain was sectioned every 200 μm, with each coronal slice being 50 μm thick. Next, the sections were incubated in a 0.1% cresyl violet solution (Sigma-Aldrich, St. Louis, MO, USA) for 7 minutes. After rapid rinsing with H2O, the slides were differentiated with 70% (v / v) ethanol containing a few drops of acetic acid, followed by dehydration with stepwise ethanol and two changes of xylene. The sections were then mounted on Fisher Chemical® Permount® Mounting Media. Results were expressed as a percentage of ipsilateral hemisphere volume (remaining brain tissue) compared to the contralateral hemisphere (27).

[0082] The values ​​are mean ± SEM. Following a one-way ANOVA, a post-hoc Newman-Keuls multiple comparison test was applied to evaluate the differences between groups.

[0083] result No deaths occurred in animals treated with the NT or HT protocol. Table 1 summarizes the results of continuous body temperature measurements in HT animals. Radiolabeling experiments showed that approximately 96% of the injected emulsion was excreted from the peritoneal cavity in both NT and HT mice 4 hours after intraperitoneal injection. Furthermore, no significant differences were observed in the organ distribution of tri-DHA emulsion particles between NT and HT mice. In both NT and HT mice, the highest uptake of emulsion particles was in the liver (44–47% of the recovered dose of radiolabeled emulsion), followed by the muscle (20–23%) and the heart (8–9%). The lowest uptake of emulsion particles was in the brain in both NT and HT animals (less than 0.3% of the recovered dose).

[0084] The inventors evaluated the neuroprotective effects of HT + tri-DHA treatment initiated immediately after HI injury. HT or tri-DHA showed a significant reduction in cerebral infarct volume (approximately 50%) compared to NT animals treated with physiological saline (Figures 1A and 1B). The combined use of HT and tri-DHA treatment immediately after HI injury did not provide any additional benefits compared to HT treatment alone.

[0085] Neuroprotection from HT+tri-DHA administration initiated immediately after HI injury was maintained even at 7 days post-ischemic injury. Nissl staining showed better preservation of the ipsilateral hemisphere in HT or HT+tri-DHA treated mice compared to the control group. However, this combination did not offer any therapeutic advantage compared to HT treatment alone. Representative Nissl-stained sections are shown in Figure 1C.

[0086] In this example, a delayed HT treatment protocol was performed to determine the therapeutic range of neuroprotection after ischemic injury. HT delayed by 2 hours after HI showed a reduction in cerebral infarct volume compared to NT animals. Furthermore, HT + tri-DHA treatment did not provide significantly additional protection than that provided by HT alone starting 2 hours after HI injury, but there was a slight tendency for further reduction in infarct size (infarct volume %): 31.4±4.1 NT + saline vs. 18.8±4.6 HT + saline vs. 12.7±4.0 HT + tri-DHA (Figures 2A and 2B). Delaying HT treatment to 4 hours after HI injury did not provide protection against ischemic injury. Combining HT with tri-DHA treatment delayed 4 hours after HI injury did not extend the therapeutic range of HT. An increase in infarct volume was observed in animals treated with the 4-hour delayed HT + tri-DHA combination, but the difference was not significant compared to NT or HT alone (Figures 2C and 2D). Therefore, our results indicate that combined treatment with tri-DHA emulsion and HT does not provide any additional significant benefits in neuroprotection in ischemic injury.

[0087] Consideration This study showed that HT administration provided neuroprotection comparable to that of tri-DHA. Furthermore, combined treatment with tri-DHA emulsion and HT did not provide additional neuroprotection.

[0088] Therapeutic hypertension (HT) is a well-established neuroprotective measure in the management of acute ischemic brain injury, including oxygen-deficient encephalopathy after cardiac arrest and perinatal asphyxia (28). Randomized trials have shown that HT is also effective in improving neurological outcomes in patients with traumatic brain injury (29). The neuroprotective benefits of systemic HT after ischemic stroke have been reported in clinical trials (7). However, the use of HT in the treatment of acute stroke remains controversial and is limited by logistical challenges (7, 30).

[0089] HT initiated immediately after HI injury has a neuroprotective effect, and the degree of neuroprotection decreases linearly with delay in the initiation of cooling (31, 32). In a neonatal mouse model of HI injury, HT initiated 0 or 2 hours after HI injury provided neuroprotection (23), while no studies have evaluated the effect of HT delayed more than 2 hours in mice. The results presented here indicate that HT has a neuroprotective effect up to 2 hours after HI injury, and protection is lost if treatment is delayed by 4 hours. In a neonatal rat model, Sabir et al. (32) showed that HT delayed up to 6 hours after HI injury provided neuroprotection. This may be related to differences in the progression of ischemic injury and neuroprotective pathways, as well as differences in metabolic rates, between mice and rats (33). We reported that administration of tri-DHA within 2 hours after HI injury significantly reduced cerebral infarct volume (approximately 50%), but tri-DHA administered 4 hours after HI injury did not show a preventive effect (20). These results of the present invention suggest that HT provides a therapeutic range very similar to that of tri-DHA treatment. In neonates with HI encephalopathy, treatment involves selective head cooling using a cooling cap, or whole-body cooling by passive cooling (turning off the radiant heater / incubator), cool packs, and / or commercially available cooling blankets (34, 35). The therapeutic range for neonatal HI encephalopathy has been suggested to be less than 6 hours (36, 37). However, HT initiated within 6–24 hours postnativity may be effective, although its efficacy is uncertain (38). The basal metabolic rate per kg of body weight in mice is seven times higher than in humans (39), which may play a significant role in extending the therapeutic range of HT for HI injury in humans. Therefore, the neuroprotective effects of a 2-hour delayed treatment in our protocol in mice may translate to a longer time range in HT in humans.

[0090] The inventors investigated whether DHA could potentially add superior neuroprotection as an adjunct therapy to enhance the effectiveness of HT after HI injury. The inventors' results suggest that combining HT and tri-DHA neither enhances neuroprotection nor expands the therapeutic range of post-HI injury treatment. This is consistent with recent findings from studies of neonatal piglet models of HI injury, where combined HT and DHA treatment offered no additional benefit over individual treatments in reducing brain injury and inflammatory markers after HI injury (40). However, another study using a neonatal rat model of HI injury showed that HT + DHA synergistically reduced cerebral infarct volume and improved behavioral capacity (41). Interestingly, the failure of HT + tri-DHA treatment to significantly enhance neuroprotection, as demonstrated in the inventors' radiolabeling experiments, was not due to reduced absorption and distribution of tri-DHA emulsion particles. Furthermore, low uptake of tri-DHA emulsion particles in the brain did not explain the effectiveness of tri-DHA in providing HI neuroprotection. Recent data have shown that injected tri-DHA emulsion is taken up by the liver, metabolized, and secreted into the plasma pool of lysophosphatidylcholine and unesterified fatty acids, thereby promoting DHA transport to the brain (22).

[0091] Both DHA and HT share a common neuroprotective pathway against HI injury. DHA and HT downregulate pro-apoptotic B-cell lymphoma 2 (BCL-2)-associated X (BAX) and upregulate anti-apoptotic BCL-2, resulting in reduced cytochrome c release and caspase activation (17, 42). Furthermore, DHA and HT promote the activation of AKT, which stimulates cell proliferation (43, 44). In addition, in experimental stroke, DHA and HT treatment has been reported to reduce microglial activation and pro-inflammatory cytokines such as interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α) (45, 46). Moreover, both treatments inhibit nuclear factor kappa B (NF-κB), a transcription factor that activates many inflammatory signaling pathways (47, 48). Furthermore, DHA and HT have been shown to prevent the accumulation or release of excitotoxic amino acids such as glutamate (49, 50). Both DHA and HT limit the acceleration of mitochondrial ROS release by reperfusion and prevent mitochondrial membrane permeability (21, 51). Therefore, it is thought that HT and DHA act through similar neuroprotective pathways, and that combined treatment may negate the further mitigating effect of brain injury.

[0092] Currently, HT is the only established treatment for moderate to severe encephalopathy in infants (52), and is a promising strategy still under investigation for the treatment of stroke in adults (53). Successful clinical application of HT for stroke requires control over various key parameters of HT treatment, such as onset time, duration, depth of HT, and rewarming rate (11). While patient cooling is conceptually simple, it is a complex medical procedure requiring coordination of efforts by specially trained medical staff, along with preparation for potential management issues that may arise with HT (12, 54). Using HT as a treatment for stroke typically requires treatment in a tertiary care hospital and involves significant financial costs (55). Our findings indicate that injection of HT or tri-DHA emulsion reduces infarct volume, and the degree of neuroprotection is comparable with both treatments. Omega-3 fatty acids are safe and well-tolerated in humans without serious side effects (56-58). Intravenous injection is a common and feasible procedure and can be easily performed in primary care settings.

[0093] Example 2: Acute injection of omega-3 diglyceride emulsion provides superior protection against hypoxic-ischemic brain injury in a neonatal mouse model compared to omega-3 triglyceride emulsion. Acute treatment with triglyceride lipid emulsions containing both EPA and DHA, or with DHA alone (tri-DHA), provides neuroprotection after hypoxic-ischemic brain injury by acting within the first few minutes / hours of reperfusion. The biological mechanisms affected by tri-DHA and its bioactive mediators are thought to include (i) reduced mitochondrial reactive oxygen species (ROS) production; (ii) preservation of mitochondrial function, as demonstrated by the maintenance of Ca2+ uptake and homeostasis; (iii) blockage of free radical production in brain mitochondria within 30 minutes after reperfusion; and (iv) inhibition of mitochondrial-related apoptotic pathways. Neuroprotection induced by acute administration of tri-DHA was also associated with increased DHA content in brain mitochondria and increased content of DHA-derived bioactive mediators such as neuroprotectin D1 (NPD1) and D-series resolvins in brain tissue. Therefore, the neuroprotective effects of direct administration of NPD1 after hypoxic-ischemic injury were further investigated. The inventors observed that NPD1 treatment induced a significant reduction in cerebral infarct volume compared to the control group, and that this was associated with both the maintenance of mitochondrial Ca2+ buffering capacity and a reduction in mitochondrial-associated cell death pathways.

[0094] The data further demonstrates that neonatal mice treated with omega-3 FA contained in DG emulsion (containing over 90% EPA and DHA of total fatty acids) showed a significant reduction in cerebral infarct volume, indicating that omega-3 DG emulsion is far more effective than omega-3 TG emulsion in the neonatal HI model. Figure 3.

[0095] The inventors characterized the chemophysical properties of omega-3 fatty acids (FAs) contained in DG emulsions and compared them with those of TG emulsions. The inventors evaluated the interaction between DG and an in vitro model of the cell membrane using NMR spectroscopy. The inventors observed that (i) DG did not adversely affect membrane structure and (ii) it was incorporated into the biological membrane system more efficiently than TG. To establish whether rapid hydrolysis promotes the clearance of diglyceride emulsions, in vitro lipolysis studies were conducted by evaluating fatty acid release via lipoprotein lipase (LpL)-mediated hydrolysis. The inventors observed that omega-3 DG emulsions were hydrolyzed more efficiently than omega-3 TG. This may explain / contribute to the faster uptake and rapid neuroprotection of DG in ischemic brain injury. These findings highlight the potential of omega-3 FAs delivered in lipid emulsions as potent neuroprotective agents in hypoxic-ischemic brain injury, including in infants.

[0096] Further studies, as shown in Figure 4, measured infarct volume in neonatal mice (10 days old) treated with hypoxic-ischemic (HI) injury and 5, 10, or 20 ng of saline or PD1 n-3 DPA per animal (n=15-17). Values ​​are mean values ​​with standard deviation. The reduction in infarct volume was dose-dependent.

[0097] References 1.Wu YW, et al.Placental pathology and neonatal brain MRI in a randomized trial of erythropoietin for hypoxic-ischemic encephalopathy.Pediatr Res(2020)87:879-884. 2.Huang L, Zhang L.Neural stem cell therapies and hypoxic-ischemic brain injury.Prog Neurobiol(2019)173:1-17. 3.Ye X,et al.Purinergic 2X7 receptor / NLRP3 pathway triggers neuronal apoptosis after ischemic stroke in the mouse.Exp Neurol(2017)292:46-55. 4.Aker K,et al.Thomas N.Therapeutic hypothermia for neonatal hypoxic-ischaemic encephalopathy in India(THIN study): a randomised controlled trial.Arch Dis Child - Fetal Neonatal Ed(2020)105:405-411. 5.Zhao Y,et al.Pharmacological hypothermia induced neurovascular protection after severe stroke of transient middle cerebral artery occlusion in mice.Exp Neurol(2020)325:113133. 6.Zgavc T,et al.Experimental and clinical use of therapeutic hypothermia for ischemic stroke: opportunities and limitations.Stroke Res Treat(2011)2011:689290. 7.Duan Y,et al.New endovascular approach for hypothermia with intrajugular cooling and neuroprotective effect in ischemic stroke.Stroke(2020)51:628-636. 8.Yenari MA,Han HS.Neuroprotective mechanisms of hypothermia in brain ischaemia.Nat Rev Neurosci(2012)13:267-278. 9.Jiang J,Yu M,Zhu C.Effect of long-term mild hypothermia therapy in patients with severe traumatic brain injury: 1-year follow-up review of 87 cases.J Neurosurg(2000)93:546-549. 10.Berger C,et al.Hypothermia and brain-derived neurotrophic factor reduce glutamate synergistically in acute stroke.Exp Neurol(2004)185:305-312. 11.Wu L,et al.Hypothermic neuroprotection against acute ischemic stroke: The 2019 update.J Cereb Blood Flow Metab(2020)40:461-481. 12.Lampe JW,Becker LB.State of the art in therapeutic hypothermia.Annu Rev Med(2011)62:79-93. 13.Kurisu K,et al.Therapeutic hypothermia and neuroprotection in acute neurological disease.Curr Med Chem(2019)26:5430-5455. 14.Yenari M,et al.Metabolic downregulation.Stroke J Cereb Circ(2008)39:2910-2917. 15.Cilio MR,Ferriero DM.Synergistic neuroprotective therapies with hypothermia.Semin Fetal Neonatal Med(2010)15:293-298. 16.Takeyama E,et al.Dietary intake of green nut oil or DHA ameliorates DHA distribution in the brain of a mouse model of dementia accompanied by memory recovery.Nutrients(2019)11:2371. 17.Mayurasakorn K,et al.Docosahexaenoic acid: brain accretion and roles in neuroprotection after brain hypoxia and ischemia.Curr Opin Clin Nutr Metab Care(2011)14:158-167. 18.Eady TN,et al.Docosahexaenoic acid complexed to albumin provides neuroprotection after experimental stroke in aged rats.Neurobiol Dis(2014)62:1-7. 19.Jiang X,et al.A post-stroke therapeutic regimen with omega-3 polyunsaturated fatty acids that promotes white matter integrity and beneficial microglial responses after cerebral ischemia.Transl Stroke Res(2016)7:548-561. 20.Williams JJ,et al.N-3 fatty acid rich triglyceride emulsions are neuroprotective after cerebral hypoxic-ischemic injury in neonatal mice. PLoS ONE(2013)8:e56233. 21.Mayurasakorn K,et al.DHA but not EPA emulsions preserve neurological and mitochondrial function after brain hypoxia-ischemia in neonatal mice.PloS One(2016)11:e0160870. 22.Manual Kollareth DJ,et al.Acute injection of a DHA triglyceride emulsion after hypoxic-ischemic brain injury in mice increases both DHA and EPA levels in blood and brain.Prostaglandins Leukot Essent Fatty Acids(2020)162:102176. 23.Reinboth BS,et al.Endogenous hypothermic response to hypoxia reduces brain injury: Implications for modeling hypoxic-ischemic encephalopathy and therapeutic hypothermia in neonatal mice.Exp Neurol(2016)283:264-275. 24.Galinsky R, et al. In the era of therapeutic hypothermia, how well do studies of perinatal neuroprotection control temperature? Dev Neurosci (2017) 39:7-22. 25.Qi K,et al.Effects of particle size on blood clearance and tissue uptake of lipid emulsions with different triglyceride compositions.J Parenter Enter Nutr(2003)27:58-64. 26.Manual Kollareth DJ,et al.Radiolabeled cholesteryl ethers: A need to analyze for biological stability before use.Biochem Biophys Rep(2018)13:1-6. 27.Zirpoli H,et al.NPD1 rapidly targets mitochondria-mediated apoptosis after acute injection protecting brain against ischemic injury.Exp Neurol(2020)113495. 28.van der Worp HB,et al.Therapeutic hypothermia for acute ischemic stroke: ready to start large randomized trials? J Cereb Blood Flow Metab(2010)30:1079-1093. 29.Dietrich WD,Bramlett HM.Therapeutic hypothermia and targeted temperature management for traumatic brain injury: Experimental and clinical experience.Brain Circ(2017)3:186-198. 30.Zhao H,Steinberg G.Limited therapeutic time windows of mild-to-moderate hypothermia in a focal ischemia model in rat.Stroke Res Treat(2011)2011: doi:10.4061 / 2011 / 131834 31.Gunn AJ.Cerebral hypothermia for prevention of brain injury following perinatal asphyxia.Curr Opin Pediatr(2000)12:111-115. 32.Sabir H,et al.Immediate hypothermia is not neuroprotective after severe hypoxia-ischemia and is deleterious when delayed by 12 hours in neonatal rats.Stroke(2012)43:3364-3370. 33.Du Y,et al.Differential subnetwork of chemokines / cytokines in human,mouse,and rat brain cells after oxygen-glucose deprivation.J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab(2017)37:1425-1434. 34.Akula VP,et al.A randomized clinical trial of therapeutic hypothermia mode during transport for neonatal encephalopathy.J Pediatr(2015)166:856-861.e2. 35.Peliowski-Davidovich A.Hypothermia for newborns with hypoxic ischemic encephalopathy.Paediatr Child Health(2012)17:41-43. 36.Kendall GS,et al.Cooling on retrieval study group. Passive cooling for initiation of therapeutic hypothermia in neonatal encephalopathy.Arch Dis Child Fetal Neonatal Ed(2010)95:F408-412. 37.Gunn AJ,Groenendaal F.Delayed neuroprotection in the era of hypothermia: What can we add? J Clin Neonatol(2016)5:3. 38.Laptook AR,et al.Effect of therapeutic hypothermia initiated after 6 hours of age on death or disability among newborns with hypoxic-ischemic encephalopathy.JAMA(2017)318:1550-1560. 39.Demetrius L.Of mice and men.EMBO Rep(2005)6:S39-S44. 40.Huun MU,et al.DHA and therapeutic hypothermia in a short-term follow-up piglet model of hypoxia-ischemia: Effects on H+MRS biomarkers.PloS One(2018)13:e0201895. 41.Berman DR,et al.Docosahexaenoic acid augments hypothermic neuroprotection in a neonatal rat asphyxia model.Neonatology(2013)104:71-78. 42.An H,et al.Phenothiazines enhance mild hypothermia-induced neuroprotection via PI3K / Akt regulation in experimental stroke.Sci Rep(2017)7:7469. 43.Eady TN,et al.Docosahexaenoic acid signaling modulates cell survival in experimental ischemic stroke penumbra and initiates long-term repair in young and aged rats.PloS One(2012)7:e46151. 44.Zhao H,et al.Akt contributes to neuroprotection by hypothermia against cerebral ischemia in rats.J Neurosci Off J Soc Neurosci(2005)25:9794-9806. 45.Cai W,et al.Post-stroke DHA Treatment Protects Against Acute Ischemic Brain Injury by Skewing Macrophage Polarity Toward the M2 Phenotype.Transl Stroke Res(2018)9:669-680. 46.Lee JH,et al.Regulation of therapeutic hypothermia on inflammatory cytokines,microglia polarization,migration and functional recovery after ischemic stroke in mice.Neurobiol Dis(2016)96:248-260. 47.Zhang W,et al.Omega-3 polyunsaturated fatty acid supplementation confers long-term neuroprotection against neonatal hypoxic-ischemic brain injury through anti-inflammatory actions. Stroke(2010)41:2341-2347. 48.Yenari MA,Han HS.Influence of hypothermia on post-ischemic inflammation: role of nuclear factor kappa B(NFkappaB).Neurochem Int(2006)49:164-169. 49.Moreira JD,et al.Dietary omega-3 fatty acids attenuate cellular damage after a hippocampal ischemic insult in adult rats.J Nutr Biochem(2010)21:351-356. 50.Zhang H,et al.Therapeutic effect of post-ischemic hypothermia duration on cerebral ischemic injury.Neurol Res(2008)30:332-336. 51.Gong P,et al.Hypothermia-induced neuroprotection is associated with reduced mitochondrial membrane permeability in a swine model of cardiac arrest.J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab(2013)33:928-934. 52.Oorschot DE,et al.Treatment of neonatal hypoxic-ischemic encephalopathy with erythropoietin alone,and erythropoietin combined with hypothermia: history,current status,and future research. Int J Mol Sci(2020)21:1487. 53.Chen J,et al.Endovascular hypothermia in acute ischemic stroke: pilot study of selective intra-arterial cold saline infusion.Stroke(2016)47:1933-1935. 54.Li L,et al.Combination treatment with methylene blue and hypothermia in global cerebral ischemia.Mol Neurobiol(2018)55:2042-2055. 55.Kim JJ,et al.Cost-effective therapeutic hypothermia treatment device for hypoxic ischemic encephalopathy.Med Devices(2013)6:1-10. 56. Zhang M-M, et al. The efficacy and safety of omega-3 fatty acids on depressive symptoms in perinatal women: a meta-analysis of randomized placebo-controlled trials. Transl Psychiatry (2020) 10: doi:10.1038 / s41398-020-00886-3. 57. Defilippis AP, et al. Omega-3 Fatty acids for cardiovascular disease prevention. Curr Treat Options Cardiovasc Med (2010) 12:365-380. 58. Calder PC, Deckelbaum RJ. Intravenous fish oil in hospitalized adult patients: reviewing the reviews. Curr Opin Clin Nutr Metab Care (2013) 16:119-123.

Table 1

Claims

1. A pharmaceutical composition comprising an omega-3 fatty acid (FA) diglyceride (DG) emulsion and / or an omega-3 FA triglyceride (TG) emulsion for protecting a subject from brain damage associated with neonatal hypoxic-ischemic encephalopathy (HIE).

2. 10. The pharmaceutical composition of claim 1, wherein the subject is a prenatal subject at risk for HIE and the pharmaceutical composition is administered to the mother during pregnancy.

3. 10. The pharmaceutical composition of claim 1, wherein the subject is in labor and the pharmaceutical composition is administered intravenously or via a nasogastric tube to the mother before or after the onset of labor.

4. 4. The pharmaceutical composition of claim 2 or 3, wherein the pharmaceutical composition is administered intravenously as one or more bolus injections or by continuous infusion, or as a combination of one or more bolus loading doses followed by the infusion of one or more additional intravenous doses.

5. 10. The pharmaceutical composition of claim 1, wherein the subject is a newborn and the pharmaceutical composition is first administered to the newborn within about 12 hours of delivery.

6. The pharmaceutical composition of claim 5, wherein the neonate is a preterm or full-term neonate.

7. 7. The pharmaceutical composition of claim 5 or 6, wherein at least a first dose of the pharmaceutical composition is administered within about 6 hours of delivery, within about 4 hours of delivery, or within about 2 hours of delivery.

8. The pharmaceutical composition according to any one of claims 5 to 7, wherein the pharmaceutical composition is administered as one or more bolus injections and / or as a continuous infusion, via a nasogastric (NG) tube or intravenously.

9. The pharmaceutical composition of any one of claims 1 to 8, wherein the neonate is treated with therapeutic hypothermia (HT).

10. 10. The pharmaceutical composition of claim 9, wherein the pharmaceutical composition is initially administered before, during, or after HT.

11. 11. The pharmaceutical composition of claim 9 or 10, wherein the HT is initiated within about 12 hours of delivery.

12. 12. The pharmaceutical composition of claim 11, wherein the HT is initiated within about 10 hours of delivery.

13. 12. The pharmaceutical composition of claim 11, wherein the HT is initiated within about 8 hours of delivery.

14. 12. The pharmaceutical composition of claim 11, wherein the HT is initiated within about 6 hours of delivery.

15. 12. The pharmaceutical composition of claim 11, wherein the HT is initiated about 6 hours post-partum, or about 8 hours post-partum, or about 10 hours post-partum, or about 12 hours post-partum.

16. The pharmaceutical composition according to any one of claims 1 to 15, comprising an omega-3 FA TG emulsion.

17. The pharmaceutical composition according to any one of claims 1 to 15, comprising an omega-3 FA DG emulsion.

18. 18. The pharmaceutical composition of claim 16 or 17, wherein the FA comprises at least about 50% by weight of the fatty acids eicosapentaenoic acid (EPA) and / or docosahexaenoic acid (DHA).

19. 20. The pharmaceutical composition of claim 18, wherein the fatty acids comprise at least about 60% by weight EPA and / or DHA.

20. 20. The pharmaceutical composition of claim 18, wherein the fatty acids comprise at least about 70% by weight EPA and / or DHA.

21. The pharmaceutical composition of any one of claims 18 to 20, wherein the fatty acid comprises both EPA and DHA.

22. 21. The pharmaceutical composition of claim 20, wherein the ratio of EPA:DHA is from about 4:1 to about 1:

4.

23. 23. The pharmaceutical composition of claim 22, wherein the ratio of EPA:DHA is from about 2:1 to about 1:

2.

24. The pharmaceutical composition of any one of claims 16 to 23, wherein the FA further comprises docosapentaenoic acid (DPA).

25. The pharmaceutical composition of any one of claims 15 to 24, wherein the FA further comprises arachidonic acid (ARA).

26. 26. The pharmaceutical composition of claim 25, wherein the FA comprises about 1 to about 40% by weight of ARA.

27. The pharmaceutical composition according to any one of claims 1 to 25, wherein the DG or TG, or an emulsion thereof, further comprises one or more specific pro-degradation mediators (SPMs).

28. 28. The pharmaceutical composition of claim 27, wherein the SPM(s) comprises one or more of lipoxins, (neuro)protectins, resolvins, and maresins.

29. 29. The pharmaceutical composition according to any one of claims 15 to 28, wherein the emulsion further comprises esterified medium chain fatty acids (MCFA) either as free FA or as TG and / or DG.

30. 30. The pharmaceutical composition of claim 29, wherein the MCFA is from about 1% to about 20% of the fatty acids in the TG and / or DG emulsion.

31. 31. The pharmaceutical composition of any one of claims 1 to 30, wherein the emulsion comprises about 10% to about 30% by weight of TG and / or DG.

32. 32. The pharmaceutical composition of claim 31, wherein the emulsion comprises about 15% to about 25% by weight of DG.

33. The pharmaceutical composition according to any one of claims 1 to 32, wherein the emulsion has a mean particle size of 200 nm or less.

34. 34. The pharmaceutical composition of claim 33, wherein the emulsion has a negative zeta potential of about -40 mV or greater.

35. The pharmaceutical composition of any one of claims 1 to 34, wherein the subject receives a single dose of the pharmaceutical composition.

36. The pharmaceutical composition of any one of claims 1 to 35, wherein the subject receives at least two and up to six doses of the pharmaceutical composition.

37. 37. The pharmaceutical composition of claim 36, wherein the pharmaceutical composition is administered no more than about once every 12 hours.

38. 37. The pharmaceutical composition of claim 36, wherein the pharmaceutical composition is administered for about 1 day to about 1 week.

39. 37. The pharmaceutical composition of claim 36, wherein the pharmaceutical composition is administered about daily.

40. The pharmaceutical composition of any one of claims 1 to 39, wherein each administration is a dose of about 0.05 to about 5 g of emulsified DG or emulsified TG per kg of body weight.

41. 41. The pharmaceutical composition of claim 40, wherein each administration is a dose of about 0.5 to about 4 g of the emulsified DG or the emulsified TG per kg of body weight.